One Shot, 20% Longer Life: The FGF21 Gene Therapy Rejuvenating Aging Mice

Researchers administered a single intramuscular injection of AAV1-FGF21 to mice at 13, 19, and 22 months of age—roughly equivalent to human ages where age-related diseases are already established. The therapy used an adeno-associated virus vector directed to skeletal muscle, turning it into a long-term biofactory that secreted native FGF21 protein continuously into the bloodstream . No additional doses, no weekly infusions, no daily pills. One shot in the muscle, and serum FGF21 levels stayed stably elevated for the rest of the animals' lives.

The headline number: treated mice experienced a 20.54% increase in life expectancy compared to littermate controls . This outcome was consistent across male and female animals, an important detail given that many anti-aging interventions have shown sex-specific effects. Equally notable was when the mice received treatment. Starting the therapy in late middle age or even geriatric-equivalent stages still produced a meaningful survival benefit, suggesting the window of opportunity isn't limited to youth.

How a Single Hormone Reprograms Whole-Body Aging

FGF21 is a liver-derived hormone that regulates energy metabolism, insulin sensitivity, and stress resistance. Elevating it through gene therapy did far more than just shift a few biomarkers. The UAB study documented cascading improvements across nearly every organ system examined :

• Body composition: Treated mice shed excess fat mass and regained leaner physiques resembling much younger animals, without losing muscle.
• Metabolic control: Insulin sensitivity and glucose tolerance improved significantly, reducing signs of age-related metabolic dysfunction.
• Heart: Untreated elderly controls showed extensive collagen deposition and amyloid pathology in cardiac tissue; in treated mice, these markers of aging heart disease were largely absent.
• Kidneys and liver: The same pattern held—fibrosis and amyloid deposits that accumulated in control animals were dramatically reduced or prevented altogether in the FGF21 treatment group.
• Physical performance: Treated mice outperformed controls on rotarod, grip strength, and hanging tests, indicating preserved neuromuscular function.
• Cognition: Open-field tests suggested that treated animals retained better exploratory behavior and cognitive function, likely reflecting protection of brain aging.

These aren't isolated metabolic tweaks. The therapy appears to trigger coordinated tissue-specific adaptations that collectively slow the systemic aging process. At the cellular level, follow-up analyses pointed to improved mitochondrial function and reduced inflammation as plausible drivers of the multi-organ protection .

Decades of Prior Work That Built the Foundation

The UAB study didn't emerge from nowhere. It represents the culmination of research stretching back more than a decade, much of it from the same group.

Earlier work by the Bosch lab established that intramuscular AAV1-FGF21 could prevent age-related weight gain, adiposity, and insulin resistance when given to young healthy mice, effectively slowing their aging trajectory from the start . Those early findings were crucial proof-of-concept, but they left a key question unanswered: could the same therapy work in animals that were already old and already showing signs of decline?

The 2026 study closed that gap, showing that late-life intervention is still powerfully effective .

Beyond the UAB group, a wide body of independent research has established FGF21 as a bona fide pro-longevity hormone across multiple contexts. Transgenic mice engineered to overexpress FGF21 from birth live significantly longer than wild-type littermates, with effects linked to blunting of the growth hormone/IGF-1 signaling axis in the liver . FGF21 has also been shown to protect against age-related thymic involution—the shrinking of the thymus gland that cripples immune function with age .

Separately, a 2025 study from UT Southwestern Medical Center demonstrated that adipocyte-specific FGF21 overexpression initiated in adulthood extended lifespan in diet-induced obese mice by up to 26% through metabolic improvements independent of growth suppression . Other groups have found that FGF21 is essential for the lifespan-extending effects of protein restriction, with FGF21-knockout mice failing to reap the metabolic benefits of a low-protein diet and suffering earlier frailty and mortality .

Finally, a 2019 Harvard-led study showed that a single combination AAV gene therapy delivering FGF21 alongside sTGFβR2 and αKlotho could completely reverse weight gain and type 2 diabetes in mice while addressing multiple age-related diseases simultaneously . FGF21 alone in that study achieved complete reversal of obesity and diabetes, foreshadowing its power as a stand-alone therapy.

The cumulative evidence position is clear: FGF21 sits at the intersection of metabolic regulation and aging biology, and delivering it as a gene therapy achieves sustained biological effects that no intermittent drug regimen has matched.

Gene Therapy vs. Conventional FGF21 Drug Development

To understand why the UAB result matters, it helps to compare it to traditional FGF21 drug development, which has been underway for years.

Recombinant FGF21 protein and engineered FGF21 analogs (Fc-fusions, pegylated variants) have shown promise in animal models of obesity and non-alcoholic steatohepatitis (NASH), improving weight, insulin sensitivity, and liver fat. However, these approaches share a fundamental limitation: FGF21 has a short biological half-life, requiring frequent injections (daily or weekly) to maintain therapeutic levels. Peak-and-trough pharmacokinetics mean that tissue exposure fluctuates, potentially limiting the depth and durability of organ-level protection.

AAV gene therapy solves this problem by permanently converting muscle tissue into a stable FGF21-production platform. One injection, continuous circulating hormone, no compliance issues, no trough periods where aging biology resumes its advance. The UAB study showed that FGF21 levels remained elevated and stable for the full 27-month observation period, effectively the rest of the animals' lives . This sustained exposure likely explains why organ pathology was so profoundly suppressed—fibrosis and amyloid take years to develop, and a therapy that only intermittently fights them may never achieve the same level of prevention.

The trade-off is that gene therapy is a one-way street: once delivered, FGF21 expression is theoretically permanent. Recombinant proteins can be stopped if side effects appear; turning off an integrated AAV transgene is far harder, though not impossible with modern regulated vectors. For chronic diseases of aging where the risk-benefit calculus favors permanent protection, gene therapy may prove transformative.

Kriya Therapeutics: The Bridge from Mice to Medicine

The AAV-FGF21 platform that produced the 20% lifespan extension result is no longer confined to academic labs. Kriya Therapeutics, a clinical-stage gene therapy company, acquired Tramontane Therapeutics in September 2023, bringing the UAB/CBATEG-derived FGF21 program under its corporate umbrella .

Kriya is developing the program under the designation KRIYA-497, with an initial indication in MASH (metabolic dysfunction-associated steatohepatitis), formerly known as NASH . The rationale is strong: MASH is a chronic liver disease driven by metabolic dysfunction, fibrosis, and inflammation—the same processes that FGF21 gene therapy powerfully reversed in aging mice. Preclinical data published by Kriya and the UAB team showed that the AAV-FGF21 therapy produced durable reversal of liver fibrosis, a result with obvious clinical relevance .

The company anticipated advancing the program into clinical trials and has positioned it within a broader pipeline spanning ophthalmology, neurology, and metabolic diseases . Kriya has raised over $800 million in cumulative funding, including a $320 million Series D round in 2025 co-led by Patient Square Capital and Premji Invest, with participation from Peter Thiel and other prominent investors . That level of financial backing signals serious intent to push this platform into human testing.

It's important to note that the company's approach and the UAB lifespan study are not identical in the target indication. The mouse longevity experiment was a pharmacology study demonstrating broad anti-aging effects. Kriya's clinical development path starts with MASH, a disease with clear regulatory endpoints and a massive unmet medical need. Success in MASH would validate the platform in humans and potentially open the door to broader aging-related indications—a path that other biotechs have pursued for metformin, rapamycin, and senolytics.

Why This Matters Beyond Mice

The lifespan-extension result grabs headlines, but the real story is about healthspan—the period of life spent free from disabling disease. The UAB mice didn't just live longer; they showed dramatically better organ function, metabolic health, and physical capacity in the months before death. Untreated mice developed the equivalent of age-related multi-organ failure, while treated mice largely didn't.

If this translates to humans, even partially, the implications are vast. A therapy that preserves heart, kidney, liver, and brain function while maintaining metabolic health could compress morbidity into a much shorter period at the very end of life, transforming the economics and human toll of aging populations.

The path from a mouse lifespan study to a proven human therapy is long and littered with failures. But the FGF21 gene therapy story has several elements that distinguish it from prior anti-aging candidates: a plausible mechanism with deep supporting biology, sustained drug exposure from a single administration, multi-organ protection documented with hard pathology endpoints, and an existing corporate vehicle with real capital and a clinical roadmap heading toward human trials.

It's not a cure for aging. But as one-shot interventions go, making old mice live 20% longer while keeping their organs pristine is about as close to a breakthrough as geroscience has come.